

# From Real World Data (RWD) to Real World Evidence (RWE)— Discussion

Samuel T. Wilkinson, MD  
Yale School of Medicine  
ISCTM, February 15, 2023



Yale SCHOOL OF MEDICINE

# Disclosures

- Dr. Wilkinson has received funding from the following sources in the last 3 years:
  - Government: NIH/NIMH, AHRQ
  - Non-profit: Brain and Behavior Research Foundation (NARSAD); Robert E. Leet and Clara Guthrie Patterson Foundation; American Foundation for Suicide Prevention
  - Research Funding from Janssen, Oui Therapeutics, and Sage Therapeutics to conduct clinical trials, administered through Yale University
- Consulting fees from Janssen, Oui, Sage

# Important Questions

- Why do we need RWE/RWD?
- In what contexts would the use of RWE/RWD be helpful/possible/most needed?
- What are the comparative costs (versus traditional RCTs)?
- When can non-randomized designs be used?

# Non-randomized Studies

- Are there examples of non-randomized RWE studies that have influenced regulatory decisions in psychiatry?
- Propensity score methods?
- Instrumental variables?
- Bradford Hill Criteria?